Newsroom
Mul-1867 Novel Drug Candidate Shows Significant Promises Against Rare Pathogens that Cause Life-Threatening Lung Infections In Cystic Fibrosis Patients

BOSTON, June 20, 2016 /PRNewswire/ — A next-generation antibiotic being developed by researchers at the New York-based pharmaceutical company TGV-inhalonix is significantly more effective than traditional drugs in fighting the rise in airway pathogens that cause life-threatening lung infections in cystic fibrosis patients, according to research presented today at ASM Microbe 2016.

TGV-inhalonix Presents Drug Candidate to Treat Mixed Resistant Lung Infections in Cystic Fibrosis

BASEL, SWITZERLAND – 9 June, 2016 – A novel new drug being developed to treat antibiotic-resistant lung infections shows significant promise for treating the often life-threatening mixed bacterial and fungal lung infections contracted by cystic fibrosis patients, according to research presented today by TGV-inhalonix at the 39th European Cystic Fibrosis Conference.

TGV-inhalonix Receives Orphan Drug Status for its Novel Antibiotic to Treat Resistant Infections in Cystic Fibrosis

NEW YORK, April 12, 2016 – TGV-Inhalonix, Inc., a New York-based pharmaceutical company, today announced that its new drug candidate for treating antibiotic-resistant bacterial lung infections in patients with cystic fibrosis has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).

Pharma Leader TGV Files for Orphan Drug Status for First in Class Antibiotic to Treat Resistant Infections in Cystic Fibrosis

TGV-Inhalonix, Inc., a New York-based pharmaceutical company, recently announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration (FDA) for its novel antibiotic Mul-1867, which shows promise in treating drug-resistant bacterial pulmonary infections in patients with cystic fibrosis.

12